Gilead’s HIV drug gets closer to getting Europe approval

(Reuters) – Gilead Sciences Inc’s experimental cocktail to treat HIV received a green light from European regulators on Friday, boosting the chances of the drug being formally approved by the European Commission. The European Medicines Agency issued a positive opinion on the treatment, Descovy, a combination of emtricitabine and tenofovir alafenamide. One of Gilead’s treatments for HIV, Truvada, is an approved drug to be taken in a PrEP regimen, a group of drugs recommended by the U.S. Centers for Disease Control and Prevention to help prevent HIV infection.
Sexual Health News Headlines – Yahoo! News